BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 27409485)

  • 1. Changes in Neovascular Lesion Hyperreflectivity After Anti-VEGF Treatment in Age-Related Macular Degeneration: An Integrated Multimodal Imaging Analysis.
    Casalino G; Bandello F; Chakravarthy U
    Invest Ophthalmol Vis Sci; 2016 Jul; 57(9):OCT288-98. PubMed ID: 27409485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. REGRESSION OF TYPE 2 NEOVASCULARIZATION INTO A TYPE 1 PATTERN AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Dolz-Marco R; Phasukkijwatana N; Sarraf D; Freund KB
    Retina; 2017 Feb; 37(2):222-233. PubMed ID: 27627752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CORRELATION BETWEEN OPTICAL COHERENCE TOMOGRAPHIC HYPERREFLECTIVE FOCI AND VISUAL OUTCOMES AFTER ANTI-VEGF TREATMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND POLYPOIDAL CHOROIDAL VASCULOPATHY.
    Lee H; Ji B; Chung H; Kim HC
    Retina; 2016 Mar; 36(3):465-75. PubMed ID: 26076214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subretinal hyperreflective exudation associated with neovascular age-related macular degeneration.
    Shah VP; Shah SA; Mrejen S; Freund KB
    Retina; 2014 Jul; 34(7):1281-8. PubMed ID: 24695062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ;
    Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variable response of subretinal hyperreflective material to anti-vascular endothelial growth factor classified with optical coherence tomography angiography.
    Maruyama-Inoue M; Sato S; Yamane S; Kadonosono K
    Graefes Arch Clin Exp Ophthalmol; 2018 Nov; 256(11):2089-2096. PubMed ID: 30173338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response of vascular pigment epithelium detachment due to age-related macular degeneration to monthly treatment with ranibizumab: the prospective, multicentre RECOVER study.
    Clemens CR; Wolf A; Alten F; Milojcic C; Heiduschka P; Eter N
    Acta Ophthalmol; 2017 Nov; 95(7):683-689. PubMed ID: 28084038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
    Sadda SR; Tuomi LL; Ding B; Fung AE; Hopkins JJ
    Ophthalmology; 2018 Jun; 125(6):878-886. PubMed ID: 29477692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association of exudation pattern with anatomical and functional outcomes in patients with Neovascular Age-Related Macular Degeneration.
    Inan S; Polat O; Karadas M; Inan UU
    Rom J Ophthalmol; 2019; 63(3):238-244. PubMed ID: 31687625
    [No Abstract]   [Full Text] [Related]  

  • 10. Changes in Fundus Autofluorescence after Anti-vascular Endothelial Growth Factor According to the Type of Choroidal Neovascularization in Age-related Macular Degeneration.
    Lee JY; Chung H; Kim HC
    Korean J Ophthalmol; 2016 Feb; 30(1):17-24. PubMed ID: 26865799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognosti implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization.
    Freeman WR; Kozak I; Yuson RM; Nigam N; Cheng L; Mojana F
    Retina; 2011 Oct; 31(9):1812-8. PubMed ID: 21866073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of the hyperautofluorescent ring associated with choroidal neovascularisation in eyes undergoing anti-VEGF therapy for wet age-related macular degeneration.
    Camacho N; Barteselli G; Nezgoda JT; El-Emam S; Cheng L; Bartsch DU; Freeman WR
    Br J Ophthalmol; 2015 Sep; 99(9):1277-83. PubMed ID: 25777818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification of the therapeutic response of intraretinal, subretinal, and subpigment epithelial compartments in exudative AMD during anti-VEGF therapy.
    Golbaz I; Ahlers C; Stock G; Schütze C; Schriefl S; Schlanitz F; Simader C; Prünte C; Schmidt-Erfurth UM
    Invest Ophthalmol Vis Sci; 2011 Mar; 52(3):1599-605. PubMed ID: 21051733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is ellipsoid zone integrity essential for visual recovery in myopic neovascularization after anti-VEGF therapy?
    Milani P; Pellegrini M; Massacesi A; Moschini S; Setaccioli M; Soranna D; Zambon A; Bottoni F; Bergamini F
    Graefes Arch Clin Exp Ophthalmol; 2017 Sep; 255(9):1713-1720. PubMed ID: 28667483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal Assessment of Ellipsoid Zone Integrity, Subretinal Hyperreflective Material, and Subretinal Pigment Epithelium Disease in Neovascular Age-Related Macular Degeneration.
    Ehlers JP; Zahid R; Kaiser PK; Heier JS; Brown DM; Meng X; Reese J; Le TK; Lunasco L; Hu M; Srivastava SK
    Ophthalmol Retina; 2021 Dec; 5(12):1204-1213. PubMed ID: 33640493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RETINAL PIGMENT EPITHELIAL TEAR AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION: Clinical Course and Long-Term Prognosis.
    Heimes B; Farecki ML; Bartels S; Barrelmann A; Gutfleisch M; Spital G; Lommatzsch A; Pauleikhoff D
    Retina; 2016 May; 36(5):868-74. PubMed ID: 26655607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
    Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
    J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of retinal pigment epithelium tear formation following intravitreal anti-vascular endothelial growth factor therapy revealed by spectral-domain optical coherence tomography.
    Nagiel A; Freund KB; Spaide RF; Munch IC; Larsen M; Sarraf D
    Am J Ophthalmol; 2013 Nov; 156(5):981-988.e2. PubMed ID: 23972309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials.
    Jaffe GJ; Ying GS; Toth CA; Daniel E; Grunwald JE; Martin DF; Maguire MG;
    Ophthalmology; 2019 Feb; 126(2):252-260. PubMed ID: 30189282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-year outcomes of anti-vascular endothelial growth factor therapy in peripapillary choroidal neovascularisation.
    Singh SR; Fung AT; Fraser-Bell S; Lupidi M; Mohan S; Gabrielle PH; Zur D; Iglicki M; M López-Corell P; Gallego-Pinazo R; Farinha C; Lima LH; Mansour AM; Casella AM; Wu L; Silva R; Uwaydat SH; Govindahari V; Arevalo JF; Chhablani J
    Br J Ophthalmol; 2020 May; 104(5):678-683. PubMed ID: 31401554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.